Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 5.29%
As of Tuesday, October 27, Oruka Therapeutics, Inc.’s ORKA share price has surged by 5.29%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Commentary & Analysis
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 9.16%
As of Monday, October 26, Oruka Therapeutics, Inc.’s ORKA share price has surged by 9.16%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 11.05%
As of Monday, October 26, Oruka Therapeutics, Inc.’s ORKA share price has surged by 11.05%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 12.14%
As of Monday, October 26, Oruka Therapeutics, Inc.’s ORKA share price has surged by 12.14%, which has investors questioning if this is right time to sell.Michael Rose
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 14.82%
As of Monday, October 26, Oruka Therapeutics, Inc.’s ORKA share price has surged by 14.82%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,343.6 | $227.8 | 71% |
|
| Shares Out (Mil) | 62.9 | 53.4 | 53% |
|
| Institutional Ownership | 97.9% | 92.9% | 76% |
|
| Float (Mil) | 56.9 | 41.2 | 50% |
|
| Beta | -0.21 | 0.95 | 3% |
|
| Avg Daily Volume (000s) | 1,011 | 513 | 70% |
|
| Price Change (52-week) |
251.6% | 47.3% | 99% |
|
| Growth | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.618) | ($2.366) | ($2.862) | |
| Month Ago EPS | ($0.618) | ($2.366) | ($2.862) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.507) | ($2.039) | ($2.492) | |
| Year/Year Chg | 11.4% | 28.0% | 105.4% | |
| Financials | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($133) | ($44) | 9% |
|
| EPS (TTM) | ($2.024) | ($1.500) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($101) | ($34) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $203 | $2 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $5,063 | $177 | 63% |
|
| Valuation | ORKA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.26 | 2.22 | 81% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (17.8%) | (47.1%) | 21% |
|
| ROE | (18.3%) | (53.3%) | 24% |
|
| Liabilities to Assets | 2.2% | 29.3% | 1% |
|
| F-Score | 4 | 2 | 34% |
|
Oruka Therapeutics, Inc. did not pass any screens on 10/27/2026.
